The use of des-gamma-carboxy prothrombin (DCP) as a predictor of the risk of recurrence of hepatocellular cancer (HCC) after liver transplant (LT) has recently gained interest, especially in view of the recent extension of the eligibility criteria of these patients for LT. The aim of the present study is to look into this important matter based on a systematic review and meta-analysis.
A systematic literature review about the role of DCP in the specific setting of LT for HCC has been conducted.
Three selected studies, which showed a high rate of homogeneity (I2 = 0.0%), confirmed that the tumor marker DCP is a useful predictive factor, indicating a 5-fold increased risk for HCC recurrence after LT (p<0.001).
The meta-analysis enabled us to underline the importance of DCP in the refinement of the eligibility criteria of HCC patients for LT. This information, based on Japanese studies performed in the setting of living-donor LT only, needs further validation in the Western world both in the setting of post-mortem and living-donor LT.
Int J Biol Markers 2017; 32(4): e370 - e374
Article Type: REVIEW
AuthorsQuirino Lai, Samuele Iesari, Giovanni Battista Levi Sandri, Jan Lerut
- • Received on 23/01/2017
- • Accepted on 27/04/2017
- • Available online on 26/05/2017
- • Published online on 31/10/2017
This article is available as full text PDF.
- Lai, Quirino [PubMed] [Google Scholar] 1, 2, * Corresponding Author (email@example.com)
- Iesari, Samuele [PubMed] [Google Scholar] 1
- Levi Sandri, Giovanni Battista [PubMed] [Google Scholar] 2
- Lerut, Jan [PubMed] [Google Scholar] 1
Starzl Abdominal Transplant Unit, University Hospitals Saint Luc, Université Catholique Louvain, Brussels - Belgium
Transplant Unit, Department of Surgery, La Sapienza University, Rome - Italy